Sandbox Reserved 1322
From Proteopedia
(Difference between revisions)
| Line 12: | Line 12: | ||
The protein is associated with the α7-nicotinic acetylcholine receptor, which is associated with neurodegenerative effects in Alzheimer's Disease and Schizophrenia. Possible pharmaceuticals targeting the α7-nicotinic acetylcholine receptor involving the α7-acetylcholine binding protein and lobeline complex could be developed, which would have particular signficance in their ability to mediate ion channels without affecting neurotransmitter release. | The protein is associated with the α7-nicotinic acetylcholine receptor, which is associated with neurodegenerative effects in Alzheimer's Disease and Schizophrenia. Possible pharmaceuticals targeting the α7-nicotinic acetylcholine receptor involving the α7-acetylcholine binding protein and lobeline complex could be developed, which would have particular signficance in their ability to mediate ion channels without affecting neurotransmitter release. | ||
Lobeline by itself is sold as a smoking aid due to its activity blocking the uptake of nicotine and its subsequent binding to nicotinic acetylcholine receptors. | Lobeline by itself is sold as a smoking aid due to its activity blocking the uptake of nicotine and its subsequent binding to nicotinic acetylcholine receptors. | ||
| - | |||
| - | == Relevance == | ||
== Structural highlights == | == Structural highlights == | ||
Revision as of 19:25, 27 February 2018
| This Sandbox is Reserved from January through July 31, 2018 for use in the course HLSC322: Principles of Genetics and Genomics taught by Genevieve Houston-Ludlam at the University of Maryland, College Park, USA. This reservation includes Sandbox Reserved 1311 through Sandbox Reserved 1430. |
To get started:
More help: Help:Editing |
Humanized Acetylcholine Binding Protein and Lobeline Complex
| |||||||||||
